Please assess the completion status of the following clinical trial:

Trial Title: New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria main study~* 18 years or older~* Anorectal, cervical/vaginal or urethral Ng infection, diagnosed by the following:~  * Ng-positive Gram-stained smear (intracellular Gram-negative diplococci and leukocytes) and/or~ * Positive for Ng by nucleic acid amplification test (NAAT) (Aptima Combo 2) and/or~ * Positive for Ng by culture~* Provide samples from the included infection site for NAAT and direct culture immediately before treatment~* Willing to abstain from anal, vaginal and oral sex until the test of cure (TOC)-visit, or use condoms during sex~* Willing and able to return for a TOC-visit 7-14 days after treatment~* Provide informed consent~* Accept intramuscular injections~Exclusion criteria main study~Pre-randomisation:~* Suspicion of a complicated Ng infection based on signs and/or symptoms indicating pelvic inflammatory disease (PID), epididymitis, prostatitis or gonococcal arthritis\*~* Another (sexually transmitted) infection or a suspicion of another infection for which systemic antimicrobial therapy is indicated~* Pregnancy, having a wish to become pregnant or breastfeeding (tested at inclusion visit)~* Not able to read/understand Dutch or English~* HIV infection if:~  * Newly diagnosed HIV infection (upon the inclusion visit) and/or~ * CD4+ cell-count \<200 cells/μL (as reported by the patient)~* Known allergy or adverse reactions to ceftriaxone, ertapenemor gentamicin~* Known renal impairment (based on estimated GFR using Cockroft and Gault formula using serum creatinin measured with a point-of-care (POC) test; cut off value renal impairment eGFR ≤ 50 ml/min)~* Known liver cirrhosis (based on history)~* Known congestive heart failure (based on history)~* Known myasthenia gravis~* Known hearing loss or balance disorder, confirmed by an ear-nose-throat (ENT)-doctor or for which an ENT doctor has been consulted and a diagnostic process is still in progress (based on history)~* Concurrent use of any of the following medication:~  * systemic antibacterial antimicrobials other than nitrofurantoin or metronidazole~ * systemic immunosuppressive drugs~ * systemic valproic acid~* Use of any antimicrobial therapy other than nitrofurantoin or metronidazole in the two weeks prior to study enrollment (based on history)~* Previous enrollment in the study~* Concurrent participation in other non-observational medical research\*~* Unlikely to adhere to the study protocol~Post-randomisation:~Exclusion of participants from the modified intention to treat analysis (mITT):~* Negative result of Ng NAAT of sample collected on T0 (the day of treatment). This could be the case in the following situations:~  1. Negative NAAT in spite of positive gram stain.~ 2. Positive NAAT on pre-study visit but spontaneous clearance of the infection in the time period between first test and return visit for treatment (=study inclusion visit). A novel sample for NAAT will be collected on the study inclusion visit just before administration of treatment; if these results are Ng-negative a participant will be excluded of mITT.~* Loss to follow-up, i.e. no study visit TOC 7-14 days after treatment administration.~Exclusion from per protocol analysis (PP):~* Exclusion of mITT~* Use of non-study related antibiotics after inclusion and prior to TOC visit~* Condomless sexual contact with the primary anatomical gonorrhea site involved after inclusion and prior to TOC visit~* Other protocol violations~Inclusion criteria PK substudy (healthy volunteers):~* 18 years or older~* Provide informed consent~Exclusion criteria PK substudy (healthy volunteers)~Pre-randomisation:~* Pregnancy, having a wish to become pregnant or breastfeeding (tested at inclusion visit)~* Not able to read/understand Dutch or English~* Known allergy or adverse reactions to ceftriaxone, ertapenem, or fosfomycin.~* Known renal impairment (based on estimated GFR using Cockroft and Gault formula using serum creatinin measured with a point-of-care (POC) test; cut off value renal impairment eGFR ≤ 50 ml/min)~* Known liver cirrhosis (based on history)~* Concurrent use of any of the following medication:~  * systemic valproic acid~ * systemic metoclopramide~* Use of any systemic antimicrobial therapy other than nitrofurantoin or metronidazole in the two weeks prior to study enrollment (based on history)~* Concurrent participation in other non-observational medical research (apart from NABOGO RCT)~* Unlikely to adhere to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ceftriaxone im (Type: ACTIVE_COMPARATOR): Current standard treatment. Ceftriaxone 500mg (single intramuscular dose) + placebo (single oral dose)
- Ertapenem im (Type: EXPERIMENTAL): Ertapenem 1000mg (single intramuscular dose) + placebo (single oral dose)
- Fosfomycin po (Type: EXPERIMENTAL): Fosfomycin oral suspension 6g (single oral dose) + placebo (single intramuscular dose)
- Gentamicin im (Type: EXPERIMENTAL): Gentamicin sulfate, injectable 5mg/kg (single intramuscular dose) + placebo (single oral dose)

Based on this trial design, predict the completion outcome and termination type (if applicable).